{"id":"arry-142886-mek-inhibitor-oral","safety":{"commonSideEffects":[{"rate":"34%","effect":"Diarrhea"},{"rate":"31%","effect":"Nausea"},{"rate":"21%","effect":"Vomiting"},{"rate":"19%","effect":"Fatigue"},{"rate":"17%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARRY-142886 is a potent and selective inhibitor of MEK1 and MEK2, enzymes that are key regulators of the MAPK/ERK signaling pathway.","oneSentence":"MEK inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:54:42.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors"}]},"trialDetails":[{"nctId":"NCT01362803","phase":"PHASE1, PHASE2","title":"AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-21","conditions":"Neurofibromatosis 1, Neurofibromatosis Type 1, NF1","enrollment":99},{"nctId":"NCT04924608","phase":"PHASE3","title":"Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-11-19","conditions":"Neurofibromatosis 1, Plexiform Neurofibroma (PN)","enrollment":145},{"nctId":"NCT02407405","phase":"PHASE2","title":"MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-01-07","conditions":"Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN)","enrollment":36},{"nctId":"NCT03801369","phase":"PHASE2","title":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","status":"TERMINATED","sponsor":"Gordon Mills, MD, PhD","startDate":"2018-12-12","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT04590235","phase":"PHASE1","title":"A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-16","conditions":"Neurofibromatosis 1, Neurofibroma Plexiform","enrollment":32},{"nctId":"NCT03326310","phase":"PHASE1","title":"Selumetinib and Azacitidine in High Risk Chronic Blood Cancers","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2018-09-04","conditions":"Chronic Myeloid Leukemia, Myelofibroses","enrollment":18},{"nctId":"NCT02151084","phase":"PHASE2","title":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2014-11","conditions":"Biliary Tract Carcinoma, Gallbladder Carcinoma","enrollment":57},{"nctId":"NCT01933932","phase":"PHASE3","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2013-09-25","conditions":"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV","enrollment":510},{"nctId":"NCT02664935","phase":"PHASE2","title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma","enrollment":423},{"nctId":"NCT03433183","phase":"PHASE2","title":"SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors","status":"COMPLETED","sponsor":"Sarcoma Alliance for Research through Collaboration","startDate":"2019-10-02","conditions":"Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1","enrollment":21},{"nctId":"NCT01750281","phase":"PHASE2","title":"Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-12-18","conditions":"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV","enrollment":212},{"nctId":"NCT02768766","phase":"PHASE1","title":"Intermittent Selumetinib for Uveal Melanoma","status":"COMPLETED","sponsor":"Shaheer A. Khan","startDate":"2017-02-28","conditions":"Uveal Melanoma","enrollment":42},{"nctId":"NCT03705507","phase":"PHASE1, PHASE2","title":"International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia","status":"TERMINATED","sponsor":"University of Birmingham","startDate":"2018-05-18","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric","enrollment":12},{"nctId":"NCT01160926","phase":"PHASE1","title":"Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial","status":"TERMINATED","sponsor":"The Christie NHS Foundation Trust","startDate":"2010-07","conditions":"Rectal Cancer","enrollment":31},{"nctId":"NCT01586624","phase":"PHASE1","title":"A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2012-01-10","conditions":"Cancer, Non Small Cell Lung Cancer","enrollment":61},{"nctId":"NCT00085787","phase":"PHASE1","title":"A Study of ARRY-142886 in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","startDate":"2004-06","conditions":"Advanced Cancer","enrollment":57},{"nctId":"NCT03109301","phase":"PHASE2","title":"Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-07","conditions":"Neoplasms, Nerve Tissue, Neurofibromatosis 1, Heredodegenerative Disorders, Nervous System","enrollment":""},{"nctId":"NCT01752569","phase":"PHASE1, PHASE2","title":"A Study of Selumetinib in Patients With Kaposi's Sarcoma","status":"TERMINATED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2012-06-15","conditions":"AIDS-related Kaposi's Sarcoma","enrollment":19},{"nctId":"NCT03004105","phase":"PHASE2","title":"MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05","conditions":"Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Advanced Lung Cancer, Recurrent Nonsmall Cell Lung Cancer","enrollment":""},{"nctId":"NCT00970359","phase":"NA","title":"Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-09","conditions":"Thyroid Cancer","enrollment":24},{"nctId":"NCT00559949","phase":"PHASE2","title":"Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12","conditions":"Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma","enrollment":39},{"nctId":"NCT01085214","phase":"PHASE2","title":"AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-03","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":37},{"nctId":"NCT00866177","phase":"PHASE2","title":"MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03","conditions":"Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma","enrollment":167},{"nctId":"NCT01217450","phase":"PHASE1","title":"Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-10","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":33},{"nctId":"NCT01166126","phase":"PHASE2","title":"Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10","conditions":"Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARRY-142886, MEK inhibitor; oral","genericName":"ARRY-142886, MEK inhibitor; oral","companyName":"Array Biopharma, now a wholly owned subsidiary of Pfizer","companyId":"array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MEK inhibitor Used for Solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}